MA54063B1 - Nouveau sel d'un inhibiteur de bcl-2, forme cristalline apparentée, son procédé de préparation et compositions pharmaceutiques le contenant - Google Patents
Nouveau sel d'un inhibiteur de bcl-2, forme cristalline apparentée, son procédé de préparation et compositions pharmaceutiques le contenantInfo
- Publication number
- MA54063B1 MA54063B1 MA54063A MA54063A MA54063B1 MA 54063 B1 MA54063 B1 MA 54063B1 MA 54063 A MA54063 A MA 54063A MA 54063 A MA54063 A MA 54063A MA 54063 B1 MA54063 B1 MA 54063B1
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical compositions
- same
- bcl
- inhibitor
- compositions containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention concerne un nouveau sel et des formes cristallines associées du composé (a), le sel étant le sel de sulfate d'hydrogène, caractérisé par son diagramme de diffraction de rayons x sur poudre, son procédé de préparation et des compositions pharmaceutiques le contenant.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306430 | 2018-10-31 | ||
| PCT/EP2019/079621 WO2020089281A1 (fr) | 2018-10-31 | 2019-10-30 | Nouveau sel d'un inhibiteur de bcl-2, forme cristalline associée, son procédé de préparation et compositions pharmaceutiques le contenant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA54063A MA54063A (fr) | 2021-09-08 |
| MA54063B1 true MA54063B1 (fr) | 2023-06-28 |
Family
ID=64270773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA54063A MA54063B1 (fr) | 2018-10-31 | 2019-10-30 | Nouveau sel d'un inhibiteur de bcl-2, forme cristalline apparentée, son procédé de préparation et compositions pharmaceutiques le contenant |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US20210355108A1 (fr) |
| EP (1) | EP3873894B1 (fr) |
| JP (2) | JP2022506137A (fr) |
| KR (1) | KR20210092750A (fr) |
| CN (1) | CN112969693A (fr) |
| AR (1) | AR116921A1 (fr) |
| AU (1) | AU2019370926B2 (fr) |
| BR (1) | BR112021007194A2 (fr) |
| CA (1) | CA3117559C (fr) |
| CL (1) | CL2021000947A1 (fr) |
| CO (1) | CO2021005077A2 (fr) |
| CR (1) | CR20210211A (fr) |
| CY (1) | CY1126057T1 (fr) |
| DK (1) | DK3873894T3 (fr) |
| DO (1) | DOP2021000074A (fr) |
| EA (1) | EA202191143A1 (fr) |
| ES (1) | ES2943511T3 (fr) |
| FI (1) | FI3873894T3 (fr) |
| GE (2) | GEP20237494B (fr) |
| HR (1) | HRP20230563T1 (fr) |
| HU (1) | HUE062000T2 (fr) |
| IL (1) | IL282565A (fr) |
| JO (1) | JOP20210072A1 (fr) |
| LT (1) | LT3873894T (fr) |
| MA (1) | MA54063B1 (fr) |
| MX (1) | MX2021004934A (fr) |
| MY (1) | MY202547A (fr) |
| NI (1) | NI202100025A (fr) |
| PE (1) | PE20211503A1 (fr) |
| PH (1) | PH12021550790A1 (fr) |
| PL (1) | PL3873894T3 (fr) |
| PT (1) | PT3873894T (fr) |
| RS (1) | RS64236B1 (fr) |
| SG (1) | SG11202103594XA (fr) |
| SI (1) | SI3873894T1 (fr) |
| TW (1) | TWI791916B (fr) |
| WO (1) | WO2020089281A1 (fr) |
| ZA (1) | ZA202102783B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4088896B1 (fr) | 2019-09-27 | 2025-01-22 | Shanghai Flyco Electrical Appliance Co., Ltd. | Rasoir électrique, appareil électroménager portatif, système de rasoir électrique et procédé de commande |
| CA3190276A1 (fr) | 2020-07-31 | 2022-02-03 | Les Laboratoires Servier | Combinaison d'un inhibiteur de bcl-2 et d'un agent hypomethylant pour le traitement de cancers, utilisations et compositions pharmaceutiques associees |
| WO2022090443A1 (fr) | 2020-10-30 | 2022-05-05 | Les Laboratoires Servier | Administration et posologie pour une combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1 |
| KR20230160303A (ko) | 2021-03-24 | 2023-11-23 | 르 라보레또레 쎄르비에르 | ５－｛５－클로로－２－[(3s)－３－[(모르폴린－４－일)메틸]－３,４－디하이드로이소퀴놀린－２(１ｈ)－카르보닐]페닐｝－１,２－디메틸－１ｈ－피롤－３－카르복실산 유도체의 신규한 합성 방법 및 약학적 화합물의 생산을 위한 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004057195A1 (de) * | 2004-11-26 | 2006-06-01 | Wilex Ag | Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon |
| WO2006073292A1 (fr) * | 2005-01-06 | 2006-07-13 | Cj Corporation | Sels d'acide inorganique de sibutramine |
| TWI405756B (zh) * | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
| CN101962387B (zh) * | 2010-09-13 | 2013-01-30 | 成都雅途生物技术有限公司 | 一种新结晶形态的氯吡格雷硫酸氢盐及其制备方法 |
| CN103664753B (zh) * | 2012-09-04 | 2017-04-26 | 上海迪赛诺化学制药有限公司 | 制备阿扎那韦硫酸氢盐a型结晶的方法 |
| FR3008975A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AU2016248376B2 (en) * | 2015-04-15 | 2020-10-08 | Beone Medicines I Gmbh | Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
-
2019
- 2019-10-30 GE GEAP201915620A patent/GEP20237494B/en unknown
- 2019-10-30 JP JP2021523309A patent/JP2022506137A/ja active Pending
- 2019-10-30 CR CR20210211A patent/CR20210211A/es unknown
- 2019-10-30 KR KR1020217015833A patent/KR20210092750A/ko not_active Withdrawn
- 2019-10-30 GE GEAP202215620A patent/GEAP202215620A/en unknown
- 2019-10-30 MA MA54063A patent/MA54063B1/fr unknown
- 2019-10-30 HR HRP20230563TT patent/HRP20230563T1/hr unknown
- 2019-10-30 US US17/286,936 patent/US20210355108A1/en not_active Abandoned
- 2019-10-30 SG SG11202103594XA patent/SG11202103594XA/en unknown
- 2019-10-30 SI SI201930557T patent/SI3873894T1/sl unknown
- 2019-10-30 MX MX2021004934A patent/MX2021004934A/es unknown
- 2019-10-30 LT LTEPPCT/EP2019/079621T patent/LT3873894T/lt unknown
- 2019-10-30 FI FIEP19800947.4T patent/FI3873894T3/fi active
- 2019-10-30 EA EA202191143A patent/EA202191143A1/ru unknown
- 2019-10-30 CN CN201980071289.7A patent/CN112969693A/zh active Pending
- 2019-10-30 WO PCT/EP2019/079621 patent/WO2020089281A1/fr not_active Ceased
- 2019-10-30 DK DK19800947.4T patent/DK3873894T3/da active
- 2019-10-30 PE PE2021000597A patent/PE20211503A1/es unknown
- 2019-10-30 EP EP19800947.4A patent/EP3873894B1/fr active Active
- 2019-10-30 CA CA3117559A patent/CA3117559C/fr active Active
- 2019-10-30 ES ES19800947T patent/ES2943511T3/es active Active
- 2019-10-30 PT PT198009474T patent/PT3873894T/pt unknown
- 2019-10-30 AU AU2019370926A patent/AU2019370926B2/en not_active Ceased
- 2019-10-30 BR BR112021007194-6A patent/BR112021007194A2/pt unknown
- 2019-10-30 AR ARP190103143A patent/AR116921A1/es not_active Application Discontinuation
- 2019-10-30 RS RS20230347A patent/RS64236B1/sr unknown
- 2019-10-30 MY MYPI2021002028A patent/MY202547A/en unknown
- 2019-10-30 PL PL19800947.4T patent/PL3873894T3/pl unknown
- 2019-10-30 HU HUE19800947A patent/HUE062000T2/hu unknown
- 2019-10-30 TW TW108139360A patent/TWI791916B/zh not_active IP Right Cessation
-
2021
- 2021-04-09 PH PH12021550790A patent/PH12021550790A1/en unknown
- 2021-04-09 NI NI202100025A patent/NI202100025A/es unknown
- 2021-04-12 JO JOP/2021/0072A patent/JOP20210072A1/ar unknown
- 2021-04-16 CL CL2021000947A patent/CL2021000947A1/es unknown
- 2021-04-21 CO CONC2021/0005077A patent/CO2021005077A2/es unknown
- 2021-04-21 DO DO2021000074A patent/DOP2021000074A/es unknown
- 2021-04-22 IL IL282565A patent/IL282565A/en unknown
- 2021-04-26 ZA ZA2021/02783A patent/ZA202102783B/en unknown
-
2023
- 2023-05-18 CY CY20231100236T patent/CY1126057T1/el unknown
-
2024
- 2024-08-27 US US18/816,347 patent/US20240417390A1/en active Pending
- 2024-11-26 JP JP2024205589A patent/JP2025028968A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA30464B1 (fr) | Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent | |
| ZA202200519B (en) | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents | |
| ZA202305593B (en) | Crystalline form iii of melanocortin receptor agonist compound and method for preparing same | |
| TW200639158A (en) | New compounds with therapeutic effect | |
| MA28133A1 (fr) | FORME CRISTALLINE ßd DU CHLORHYDRATE DE L'IVABRADINE, SON PROCEDE DE PREPARATION, ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT. | |
| MA28450B1 (fr) | Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent | |
| MA28132A1 (fr) | FORME CRISTALLINE GAMMAd DU CHLORHYDRATE DE L'IVABRADINE, SON PROCEDE DE PREPARATION, ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT. | |
| EP2277857A3 (fr) | Nouvelle forme cristalline V de l'agomélatine, son procédé de préparation et les compositions pharmaceutiques qui la contiennent | |
| JOP20230086A1 (ar) | الشكل البلوري ii لمركب ناهض مستقبلات الميلانوكورتين وطريقة تحضيره | |
| PH12021550790A1 (en) | Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same | |
| MX2020000268A (es) | Agonista de fxr. | |
| CA2415438A1 (fr) | Forme cristalline .alpha. du sel de tert-butylamine du perindopril | |
| MA28449B1 (fr) | Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent | |
| ZA202305594B (en) | Crystalline form i of melanocortin receptor agonist compound, and method for preparing same | |
| MX2007006374A (es) | Derivados del 5-hidroxi-benzotiazol que tienen actividad agonista del adrenoreceptor-beta-2. | |
| ZA202305590B (en) | Crystal form iv of melanocortin receptor agonist compound, and preparation method therefor | |
| CA2415442A1 (fr) | Nouvelle forme cristalline .beta. du sel de tert-butylamine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent | |
| PH12020000100A1 (en) | Method for preparing percursor of nickel-cobalt-manganese ternary material | |
| TNSN00187A1 (fr) | Sel polymorphe nouveau | |
| MX2023013044A (es) | Forma cristalina v del compuesto agonista del receptor de melanocortina y metodo para preparar la misma. | |
| MA28191A1 (fr) | Nouvelle forme cristalline "alpha" du sel de tert -butylamine du perindoprill, son procede de preparation et les compositions pharmaceutiques qui la contiennent. | |
| MA28189A1 (fr) | Nouvelle forme cristalline y du sel de tert-butylamine du perindoprill, son procede de preparation et les compositions pharmaceutiques qui la contiennent | |
| MA28192A1 (fr) | NOUVELLE FORME CRISTALLINE ß DU SEL DE TERT-BUTYLAMINE DU PERINDOPRILL, SON PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT. | |
| MX2024005065A (es) | Sintesis de agentes formadores de complejos limitados. | |
| SA522431667B1 (ar) | مركبات بيبريدينيل- ميثيل-بورين أمين في صورة مثبطات nsd2 وعوامل مضادة للسرطان |